Similar articles for PMID: 29858958

Year	Number of Results
1993	1
1995	1
1997	3
1998	3
1999	2
2000	3
2001	2
2002	2
2003	5
2004	9
2005	4
2006	8
2007	6
2008	4
2009	6
2010	5
2011	9
2012	7
2013	3
2014	6
2015	6
2016	8
2017	4
2018	6
2019	3
2020	4
2021	4
2022	5
2023	3
2024	0

1

Process optimization for the rapid production of adenoviral vectors for clinical trials in a disposable bioreactor system.

Chen KD, Wu XX, Yu DS, Ou HL, Li YH, Zhou YQ, Li LJ. Chen KD, et al. Appl Microbiol Biotechnol. 2018 Aug;102(15):6469-6477. doi: 10.1007/s00253-018-9091-5. Epub 2018 Jun 2. Appl Microbiol Biotechnol. 2018. PMID: 29858958

2

[Producing Ad-IFN gamma by suspension culture of HEK293 cells in a disposable bioreactor].

Wu Q, Huang W. Wu Q, et al. Sheng Wu Gong Cheng Xue Bao. 2014 Nov;30(11):1786-90. Sheng Wu Gong Cheng Xue Bao. 2014. PMID: 25985530 Chinese.

3

Process Development of Adenoviral Vector Production in Fixed Bed Bioreactor: From Bench to Commercial Scale.

Lesch HP, Heikkilä KM, Lipponen EM, Valonen P, Müller A, Räsänen E, Tuunanen T, Hassinen MM, Parker N, Karhinen M, Shaw R, Ylä-Herttuala S. Lesch HP, et al. Hum Gene Ther. 2015 Aug;26(8):560-71. doi: 10.1089/hum.2015.081. Hum Gene Ther. 2015. PMID: 26176404

4

Production of oncolytic adenovirus and human mesenchymal stem cells in a single-use, Vertical-Wheel bioreactor system: Impact of bioreactor design on performance of microcarrier-based cell culture processes.

Sousa MF, Silva MM, Giroux D, Hashimura Y, Wesselschmidt R, Lee B, Roldão A, Carrondo MJ, Alves PM, Serra M. Sousa MF, et al. Biotechnol Prog. 2015 Nov-Dec;31(6):1600-12. doi: 10.1002/btpr.2158. Epub 2015 Sep 4. Biotechnol Prog. 2015. PMID: 26289142

5

Benchmarking of Scale-X Bioreactor System in Lentiviral and Adenoviral Vector Production.

Leinonen HM, Lepola S, Lipponen EM, Heikura T, Koponen T, Parker N, Ylä-Herttuala S, Lesch HP. Leinonen HM, et al. Hum Gene Ther. 2020 Mar;31(5-6):376-384. doi: 10.1089/hum.2019.247. Hum Gene Ther. 2020. PMID: 32075423 Free PMC article.

6

Integrated strategy for the production of therapeutic retroviral vectors.

Carrondo M, Panet A, Wirth D, Coroadinha AS, Cruz P, Falk H, Schucht R, Dupont F, Geny-Fiamma C, Merten OW, Hauser H. Carrondo M, et al. Hum Gene Ther. 2011 Mar;22(3):370-9. doi: 10.1089/hum.2009.165. Epub 2011 Mar 2. Hum Gene Ther. 2011. PMID: 21043806 Free article.

7

Optimization and scale-up of cell culture and purification processes for production of an adenovirus-vectored tuberculosis vaccine candidate.

Shen CF, Jacob D, Zhu T, Bernier A, Shao Z, Yu X, Patel M, Lanthier S, Kamen A. Shen CF, et al. Vaccine. 2016 Jun 17;34(29):3381-7. doi: 10.1016/j.vaccine.2016.04.090. Epub 2016 May 4. Vaccine. 2016. PMID: 27154390

8

Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor.

Wang X, Olszewska M, Qu J, Wasielewska T, Bartido S, Hermetet G, Sadelain M, Rivière I. Wang X, et al. J Immunother. 2015 Apr;38(3):127-35. doi: 10.1097/CJI.0000000000000072. J Immunother. 2015. PMID: 25751502 Free PMC article.

9

Production of Recombinant Adeno-associated Virus Vectors Using Suspension HEK293 Cells and Continuous Harvest of Vector From the Culture Media for GMP FIX and FLT1 Clinical Vector.

Grieger JC, Soltys SM, Samulski RJ. Grieger JC, et al. Mol Ther. 2016 Feb;24(2):287-297. doi: 10.1038/mt.2015.187. Epub 2015 Oct 6. Mol Ther. 2016. PMID: 26437810 Free PMC article.

10

Development and Optimization of AAV hFIX Particles by Transient Transfection in an iCELLis(®) Fixed-Bed Bioreactor.

Powers AD, Piras BA, Clark RK, Lockey TD, Meagher MM. Powers AD, et al. Hum Gene Ther Methods. 2016 Jun;27(3):112-21. doi: 10.1089/hgtb.2016.021. Hum Gene Ther Methods. 2016. PMID: 27229773

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

119 results

Results by year